Antisoma starts trials of TheraFab
Antisoma of the UK has started the first clinical trials of TheraFab, acandidate treatment for patients with non-small cell lung cancer. TheraFab is the third drug from Antisoma to reach the clinical stage of development, after TheraGyn for ovarian and gastric cancer and Therex for breast cancer.
The new agent is an injectable radio-labelled antibody fragment which will be used in tandem with external beam radiotherapy, a standard component of lung cancer treatment. TheraFab is designed to improve tumor control by increasing the amount of radiation delivered to a cancer site, without raising the exposure of healthy surrounding tissues. The technology may also be of use in other solid tumors, such as breast cancer.
The Phase I study, designed to test the distribution of the antibody in the body, will initially be conducted in Australia, with additional European centers joining the program during 2001.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze